The turmeric extract curcumin reduces oxidative and inflammatory damage in people with metabolic syndrome

  • In a new study published today it was shown that curcuminoids, curcumin and it's analogs contained in the turmeric plant, combined with piperine, a pepper extract, reduce inflammatory markers in the blood in people who suffer from metabolic syndrome (pre-diabetes)
  • Specifically, the curcuminoid/piperine combination reduced levels of malondialdehyde (MDA), a marker of fat oxidation; increased the activity of the body's own natural antioxidant enzyme superoxide dismutase (SOD); and significantly reduced levels of the inflammatory protein C-reactive protein (CRP), which is a very important risk marker and risk factor of cardiovascular disease (people with metabolic syndrome have a very high risk of cardiovascular heart disease).
  • This randomised, placebo controlled clinical trial on humans shows that even "short-term supplementation with a curcuminoid-piperine combination significantly improves oxidative and inflammatory status in patients with metabolic syndrome" and that "curcuminoids could be regarded as natural, safe and effective CRP-lowering agents."
  • Curcumin is already widely researched, and widely used, for it's antioxidant, anti-inflammatory and anti-cancer action, so the results of this study are hardly surprising and confirm what was shown in other studies, but in a clinical, randomised, placebo-controlled setup.
  • It is important to note here that curcuminoids are the sole active agents that accomplish the beneficial effects in inflammation/oxidation status, with the piperine acting as an absorption enhancer.
  • However, piperine is not absolutely necessary, as it enhances absorption only by a small factor, in contract to curcumin in liposome form, which is much more bioavailable, so our suggestion would be to use liposomal curcumin for maximum results.
  • The same antioxidant and anti-inflammatory action of curcumin that helps with prevention of cardiovascular disease is also beneficial in anti-ageing and cellulite creams, if curcumin is included in a high-purity, high-concentration form.
  • Source: Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomised controlled trial and an updated meta-analysis.
  • Abstract: BACKGROUND: Oxidative stress and inflammation have been proposed as emerging components of metabolic syndrome (MetS). Curcuminoids are natural polyphenols with strong antioxidant and anti-inflammatory properties. OBJECTIVE: To study the effectiveness of supplementation with a bioavailable curcuminoid preparation on measures of oxidative stress and inflammation in patients with MetS. Our secondary aim was to perform a meta-analysis of data from all randomized controlled trials in order to estimate the effect size of curcuminoids on plasma C-reactive protein (CRP) concentrations. METHODS: In this randomized double-blind placebo-controlled trial, 117 subjects with MetS (according to the NCEP-ATPIII diagnostic criteria) were randomly assigned to curcuminoids (n = 59; drop-outs = 9) or placebo (n = 58; drop-outs = 8) for eight weeks. Curcuminoids were administered at a daily dose of 1 g, and were co-supplemented with piperine (10 mg/day) in order to boost oral bioavailability. Serum activities of superoxide dismutase (SOD) and concentrations of malondialdehyde (MDA) and CRP were measured at baseline and at study end. Regarding the importance of CRP as a risk marker and risk factor of cardiovascular disease, a random-effects meta-analysis of clinical trials was performed to estimate the overall impact of curcuminoid therapy on circulating concentrations of CRP. The robustness of estimated effect size was evaluated using leave-one-out sensitivity analysis. RESULTS: Supplementation with curcuminoid-piperine combination significantly improved serum SOD activities (p < 0.001) and reduced MDA (p < 0.001) and CRP (p < 0.001) concentrations compared with placebo. Quantitative data synthesis revealed a significant effect of curcuminoids vs. placebo in reducing circulating CRP concentrations (weighed mean difference: -2.20 mg/L; 95% confidence interval [CI]: -3.96, -0.44; p = 0.01). This effect was robust in sensitivity analysis. CONCLUSIONS: Short-term supplementation with curcuminoid-piperine combination significantly improves oxidative and inflammatory status in patients with MetS. Curcuminoids could be regarded as natural, safe and effective CRP-lowering agents.

< Back to curcumin